SENTHIL DAMODARAN to Quinazolines
This is a "connection" page, showing publications SENTHIL DAMODARAN has written about Quinazolines.
Connection Strength
0.222
-
Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. J Clin Oncol. 2022 05 10; 40(14):1552-1561.
Score: 0.146
-
Targeting the human epidermal growth factor receptor 2 pathway in breast cancer. Hosp Pract (1995). 2012 Oct; 40(4):7-15.
Score: 0.076